Knuuttila, A <br/><br/>
Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma--a feasibility study.  [electronic resource] 

 -  Anti-cancer drugs  Apr 2000 
 - 257-61 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Controlled Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>0959-4973 
<br/><br/><label>Standard No.: </label>10.1097/00001813-200004000-00005  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Agents, Phytogenic--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Camptothecin--administration & dosage<br/>Docetaxel<br/>Feasibility Studies<br/>Female<br/>Humans<br/>Irinotecan<br/>Male<br/>Mesothelioma--drug therapy<br/>Middle Aged<br/>Neoplasm Staging<br/>Neutropenia--chemically induced<br/>Paclitaxel--administration & dosage<br/>Pleural Neoplasms--drug therapy<br/>Survival Rate<br/>Taxoids<br/>Treatment Outcome